<DOC>
	<DOC>NCT00297817</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.</brief_summary>
	<brief_title>Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Adolescents between and including 1118 years of age, who provide written informed consent. Previous or suspected disease caused by N. meningitidis; or previous immunization with a serogroup B meningococcal vaccine; Any acute, chronic or progressive disease.</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Meningococcal Disease; Meningococcal Meningitis; Vaccine</keyword>
</DOC>